Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHERSYS, INC / NEWATHX · Entity 95922 | Director | January 09, 2023 | January 11, 2023 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | June 01, 2026 | June 03, 2026 |
| SiteOne Landscape Supply, Inc.SITE · Entity 4018 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHERSYS, INC / NEW
Report date January 09, 2023 · Filed January 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,141 |
Reported balance
After 2023-01-09 transaction · row 1
1 source rowRow 1 · 2023-01-09 · Grant · Acquired 22,321 · Balance 35,141 F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.
EXELIXIS, INC.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,384 |
Reported balance
After 2026-06-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-01 · Sale · Disposed 3,925 · Balance 284,384 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025. F2: Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
F2: Includes 8,367 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.
SiteOne Landscape Supply, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,120 |
Reported balance
After 2026-05-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 1,186 · Balance 19,120 F1: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 13, 2026. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company. F2: Includes deferred stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents deferred stock units granted as director fees. The deferred stock units vest in full upon the earlier of (i) the day preceding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 13, 2026. Settlement is deferred until the earlier of the Reporting Person's termination of board service and a change in control of the Company.
F2: Includes deferred stock units.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date December 01, 2003 · Filed December 03, 2003
Section 16 reporting ended · disclosed 2003-12-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 120,081 |
Ending reported balance
After 2003-12-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2003-12-01 · Exercise / conversion · Acquired 27,122 · Balance 130,728 F1: Not Applicable. Row 2 · 2003-12-01 · Tax withholding · Disposed 10,647 · Balance 120,081 |
| Deferred Stock Unit AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 67,858 |
Reported balance
After 2003-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2003-12-01 · Exercise / conversion · Disposed 27,122 · Balance 67,858 F2: Not Applicable. F5: Not Applicable. F3: Not Applicable. F4: Not Applicable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.13 · Expires 2008-02-22 | Direct | 70,800 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 70,800 F7: These options are currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.06 · Expires 2009-02-21 | Direct | 67,200 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 67,200 F7: These options are currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.75 · Expires 2010-02-21 | Direct | 67,200 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 67,200 F7: These options are currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.04 · Expires 2010-09-24 | Direct | 260,000 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 260,000 F8: Options were granted on September 25, 2000 and by their terms are exercisable, if reporting person is employed by the Issuer, in one-third increments on September 26 of each 2003, 2004 and 2005. F11: The terms of the option grant provide that in the event of retirement under a retirement plan of the Issuer or a subsidiary: (i) on or after normal retirement date, the shares granted hereby shall continue to vest according to the schedule in footnote 8; or (ii) on an early retirement date, the shares granted hereby shall become exercisable only to the extent approved by the Committee but in no event shall shares be exercisable hereunder if such early retirement date is prior to September 26, 2003. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.05 · Expires 2011-02-25 | Direct | 138,000 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 138,000 F7: These options are currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.68 · Expires 2012-02-24 | Direct | 138,000 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 138,000 F7: These options are currently exercisable. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2005-12-10 | Direct | 240,000 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 240,000 F6: Options were granted on December 11, 1995 and by their terms are exercisable, if reporting person is employed by the Issuer, in twenty percent increments on December 12 of each 2000, 2001, 2002, 2003 and 2004. F10: The terms of the option grant provide that in the event of retirement under a retirement plan of the Issuer or a subsidiary: (i) on or after normal retirement date, 100% of the shares granted hereby shall become fully exercisable as of such retirement date; or (ii) on an early retirement date, the shares granted hereby shall become exercisable only to the extent approved by the Committee but in no event shall shares be exercisable hereunder if such early retirement is prior to December 12, 1996. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.85 · Expires 2013-02-23 | Direct | 138,000 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 138,000 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.85 · Expires 2013-02-23 | Direct | 108,100 |
Reported balance
Holding disclosure · report date 2003-12-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 108,100 F9: Options were granted on February 24, 2003 and are exercisable in one-third increments on February 25 of each 2004, 2005 and 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Not Applicable.
F2: Not Applicable.
F3: Not Applicable.
F4: Not Applicable.
F5: Not Applicable.
F6: Options were granted on December 11, 1995 and by their terms are exercisable, if reporting person is employed by the Issuer, in twenty percent increments on December 12 of each 2000, 2001, 2002, 2003 and 2004.
F7: These options are currently exercisable.
F8: Options were granted on September 25, 2000 and by their terms are exercisable, if reporting person is employed by the Issuer, in one-third increments on September 26 of each 2003, 2004 and 2005.
F9: Options were granted on February 24, 2003 and are exercisable in one-third increments on February 25 of each 2004, 2005 and 2006.
F10: The terms of the option grant provide that in the event of retirement under a retirement plan of the Issuer or a subsidiary: (i) on or after normal retirement date, 100% of the shares granted hereby shall become fully exercisable as of such retirement date; or (ii) on an early retirement date, the shares granted hereby shall become exercisable only to the extent approved by the Committee but in no event shall shares be exercisable hereunder if such early retirement is prior to December 12, 1996.
F11: The terms of the option grant provide that in the event of retirement under a retirement plan of the Issuer or a subsidiary: (i) on or after normal retirement date, the shares granted hereby shall continue to vest according to the schedule in footnote 8; or (ii) on an early retirement date, the shares granted hereby shall become exercisable only to the extent approved by the Committee but in no event shall shares be exercisable hereunder if such early retirement date is prior to September 26, 2003.
XOMA Royalty Corp
Report date July 14, 2026 · Filed July 15, 2026
Section 16 reporting ended · disclosed 2026-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Other · Disposed 21,828 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F2: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2027-02-10 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Disposition to issuer · Disposed 8,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.40 · Expires 2027-09-15 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-14 · Disposition to issuer · Disposed 2,366 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.16 · Expires 2028-05-17 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-14 · Disposition to issuer · Disposed 5,052 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.59 · Expires 2029-05-16 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-14 · Disposition to issuer · Disposed 8,167 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.27 · Expires 2030-05-20 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-14 · Disposition to issuer · Disposed 6,152 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.04 · Expires 2031-05-19 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-14 · Disposition to issuer · Disposed 5,101 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.86 · Expires 2032-05-18 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-14 · Disposition to issuer · Disposed 8,996 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.39 · Expires 2033-05-17 | Direct | 0 |
Reported balance
After 2026-07-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-14 · Disposition to issuer · Disposed 10,967 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement. F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option. F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger on May 16, 2026 (as amended, the "Merger Agreement"), by and among XOMA Royalty Corporation (the "Issuer"), Ligand Pharmaceuticals Incorporated ("Parent"), Flex Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), and XOMA Royalty Holdings Corporation ("HoldCo"). Pursuant to the Merger Agreement, on July 14, 2026, the Issuer effected a holding company reorganization, and Merger Sub merged with and into HoldCo (the "Merger"), with HoldCo surviving the Merger as a wholly-owned subsidiary of Parent. Unless context otherwise requires, all references in this Form 4 to the "Issuer" refer to HoldCo, which assumed all obligations of the Issuer under the Merger Agreement.
F2: At the time the Merger became effective (the "Effective Time"), pursuant to the Merger Agreement, each issued and outstanding share of common stock, par value $0.0075 per share, of the Issuer (the "Shares") (other than certain Shares cancelled pursuant to the Merger Agreement and Dissenting Shares (as defined in the Merger Agreement)) automatically converted into the right to receive (i) $39.00 per Share in cash, without interest, and subject to deduction for any required withholding tax (the "Closing Amount"), plus (ii) an amount of contingent value rights (each, a "CVR") representing a right to receive certain contingent payments subject to and in accordance with the terms of the CVR Agreement (as defined in the Merger Agreement) (the Closing Amount plus CVR, the "Merger Consideration").
F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding restricted stock unit ("RSU") became fully vested and cancelled and converted into the right to receive (A) an amount in cash, without interest, and subject to deduction for any required withholding tax, equal to the product of (i) the number of Shares subject to such RSU and (ii) the Closing Amount, plus (B) one CVR for each Share subject to such RSU.
F4: At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, a "Company Stock Option") that had an exercise price per Share that was less than the sum of the Closing Amount and the fair market value of one CVR (each, a "Terminating Company Stock Option") became fully vested and was cancelled, and in exchange therefor, the holder received (i) an amount in cash, without interest, and subject to deduction for any required withholding taxes, equal to the product of (A) the excess of the Closing Amount over the exercise price per Share with respect to such Terminating Company Stock Option and (B) the number of Shares subject to such Terminating Company Stock Option, plus (ii) one CVR with respect to each Share subject to such Terminating Company Stock Option.
F5: As of immediately prior to the Effective Time, each Company Stock Option that did not constitute a Terminating Company Stock Option was cancelled and no consideration was delivered in exchange therefor.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2021 Filed May 21, 2021 20:30 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 5,101 | $0.00 Strike: $31.04 | $0.00 |
DisclosureSEC source: 0001214659-21-005813 · marketforms-52857.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Common Shares · 5,101 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 19, 2021), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:24 UTC | SiteOne Landscape Supply, Inc. SITE · Entity 4018 | GrantCommon Shares | 668 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-066898 · tm2116479-7_4.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,106 F1 · shares: Represents deferred share units granted as director fees. The deferred share units vest in full upon the earlier of (i) the day proceeding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 12, 2021. Settlement is deferred until the earlier of the reporting person's termination of board service and a change in control of the Company. F2 · balance_after: Includes deferred share units. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · derivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2021-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 29, 2014. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 6,220 | $22.64 | $140,820.80 |
DisclosureSEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,589 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2021. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.91. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| March 29, 2021 Filed Apr 1, 2021 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $3.38 | $135,200.00 |
DisclosureSEC source: 0000939767-21-000038 · wf-form4_161723893234049.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 10, 2020 Filed Nov 14, 2020 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 62,403 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000939767-20-000151 · wf-form4_160531670904103.xml · derivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,403 shares Expires 2020-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 62,403 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2013. Read SEC document |
| November 10, 2020 Filed Nov 14, 2020 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 34,000 | $20.61 | $700,740.00 |
DisclosureSEC source: 0000939767-20-000151 · wf-form4_160531670904103.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,809 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.60 to $20.71. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| November 10, 2020 Filed Nov 14, 2020 01:18 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 62,403 | $5.82 | $363,185.46 |
DisclosureSEC source: 0000939767-20-000151 · wf-form4_160531670904103.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,728 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 00:41 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001368148-20-000071 · wf-form4_159252729697719.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| May 21, 2020 Filed May 23, 2020 00:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 15,456 | $0.00 Strike: $24.62 | $0.00 |
DisclosureSEC source: 0000939767-20-000093 · wf-form4_159019537087510.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,456 Underlying: Common Stock · 15,456 shares Expires 2027-05-20 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 21, 2020 Filed May 23, 2020 00:56 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 7,728 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000093 · wf-form4_159019537087510.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,406 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 21, 2021, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 18,045 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 20, 2020 Filed May 27, 2020 18:30 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 6,152 | $0.00 Strike: $21.27 | $0.00 |
DisclosureSEC source: 0001214659-20-005066 · marketforms-48898.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,152 Underlying: Common Shares · 6,152 shares Expires 2030-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over the 12-month period following the date of grant (May 20, 2020), provided that the final installment will occur on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:01 UTC | SiteOne Landscape Supply, Inc. SITE · Entity 4018 | GrantCommon Shares | 1,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-062816 · tm2019969-6_4.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,438 F1 · shares: Represents deferred share units granted as director fees. The deferred share units vest in full upon the earlier of (i) the day proceeding the Company's next annual meeting of stockholders and (ii) the first anniversary of May 13, 2020. Settlement is deferred until the earlier of the reporting person's termination of board service and a change in control of the Company. F2 · balance_after: Includes deferred share units. Read SEC document |
| April 03, 2020 Filed Apr 4, 2020 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · derivative · entry 5 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| April 03, 2020 Filed Apr 4, 2020 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · derivative · entry 4 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| April 03, 2020 Filed Apr 4, 2020 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 13,848 | $16.57 | $229,461.36 |
DisclosureSEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,678 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.34 to $16.80. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 03, 2020 Filed Apr 4, 2020 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $4.58 | $137,400.00 |
DisclosureSEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 4, 2020 00:38 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-20-000046 · wf-form4_158596070667563.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 19:02 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001209191-19-037051 · doc4.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:40 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 20,634 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000939767-19-000133 · wf-form4_155874478556734.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,634 Underlying: Common Stock · 20,634 shares Expires 2026-05-22 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 23, 2019 Filed May 25, 2019 00:40 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 10,317 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000133 · wf-form4_155874478556734.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,526 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 23, 2020, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 10,317 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 16, 2019 Filed May 20, 2019 20:44 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 8,167 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001190725-19-000020 · edgardoc.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,167 Underlying: Common Shares · 8,167 shares Expires 2029-05-16 F1 · derivative.exercise_date: All of the shares subject to this option shall vest and become exercisable monthly over one-year of the Vesting Commencement Date (May 16, 2019). Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:19 UTC | SiteOne Landscape Supply, Inc. SITE · Entity 4018 | GrantCommon Shares | 1,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-027060 · tv521914_4.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,210 F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units are fully vested on grant, but settlement is deferred until the earlier of Mr. Wyszomierski's termination of board service or a change in control of the Issuer. F2 · balance_after: Includes deferred stock units. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · derivative · entry 5 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · derivative · entry 4 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 7,822 | $23.97 | $187,493.34 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,209 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.88 to $24.12. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:09 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000084 · wf-form4_155433655136837.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 21:13 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-18-038626 · doc4.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-18 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| May 24, 2018 Filed May 25, 2018 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 15,874 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000939767-18-000111 · wf-form4_152720827542405.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,874 Underlying: Common Stock · 15,874 shares Expires 2025-05-23 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 24, 2018 Filed May 25, 2018 00:31 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 7,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-18-000111 · wf-form4_152720827542405.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,781 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 17, 2018 Filed May 22, 2018 01:15 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 5,052 | $0.00 Strike: $25.16 | $0.00 |
DisclosureSEC source: 0001190725-18-000026 · edgardoc.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,052 Underlying: Common Shares · 5,052 shares Expires 2028-05-17 F1 · derivative.exercise_date: All of the shares subject to this option shall vest and become exercisable on the one-year anniversary of the vesting commencement date (May 17, 2018). Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:05 UTC | SiteOne Landscape Supply, Inc. SITE · Entity 4018 | GrantCommon Shares | 1,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-029807 · tv494594_form4.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,621 F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units are fully vested on grant, but settlement is deferred until the earlier of Mr. Wyszomierski's termination of board service and a change in control of the Issuer. F2 · balance_after: Includes deferred stock units. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0000939767-18-000055 · wf-form4_152409672663943.xml · derivative · entry 5 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0000939767-18-000055 · wf-form4_152409672663943.xml · derivative · entry 4 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2008. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 14,959 | $20.25 | $302,919.75 |
DisclosureSEC source: 0000939767-18-000055 · wf-form4_152409672663943.xml · nonDerivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,844 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 28, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.04 to $20.74. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $11.66 | $174,900.00 |
DisclosureSEC source: 0000939767-18-000055 · wf-form4_152409672663943.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2018 Filed Apr 19, 2018 00:12 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $7.97 | $119,550.00 |
DisclosureSEC source: 0000939767-18-000055 · wf-form4_152409672663943.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 5,843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 15, 2017 Filed Feb 28, 2018 23:23 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 2,366 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001190725-18-000013 · edgardoc.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,366 Underlying: Common Shares · 2,366 shares Expires 2027-09-15 F1 · derivative.exercise_date: Shares subject to this option shall vest in equal monthly installments over one year from the grant date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 14:52 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 30,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-17-038710 · doc4.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000113 · wf-form4_149584620186199.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,686 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 5,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000113 · wf-form4_149584620186199.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,803 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 25, 2018, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 5.843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 16, 2017 Filed Jun 1, 2017 21:13 UTC | SiteOne Landscape Supply, Inc. SITE · Entity 4018 | GrantCommon Shares | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036852 · doc4.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,481 F1 · shares: Represents deferred stock units granted as director fees. The deferred stock units are fully vested on grant, but settlement is deferred until the earlier of Mr. Wyszomierski's termination of board service and a change in control of the Issuer. F2 · balance_after: Includes deferred stock units. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 22:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0000939767-17-000051 · wf-form4_149099971426992.xml · derivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 22:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 5,150 | $21.57 | $111,085.50 |
DisclosureSEC source: 0000939767-17-000051 · wf-form4_149099971426992.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,960 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2016. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.32 to $21.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 31, 2017 Filed Mar 31, 2017 22:35 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 10,000 | $10.53 | $105,300.00 |
DisclosureSEC source: 0000939767-17-000051 · wf-form4_149099971426992.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2017 Filed May 22, 2017 22:48 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0000791908-17-000031 · edgardoc.xml · derivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Shares · 8,000 shares Expires 2027-02-10 F1 · date: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2 · derivative.exercise_date: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. Read SEC document |
| December 01, 2003 Filed Dec 3, 2003 21:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionDeferred Stock Unit Award · Derivative | 27,122 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000310158-03-000149 · wys259.xml · derivative · entry 3 WYSZOMIERSKI JACK L · CIK 0001023225 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,858 Underlying: Common Shares · 27,122 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not Applicable. F5 · price: Not Applicable. F3 · derivative.exercise_date: Not Applicable. F4 · derivative.expiration_date: Not Applicable. Read SEC document |
| December 01, 2003 Filed Dec 3, 2003 21:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | Tax withholdingCommon Shares | 10,647 | $16.63 | $177,059.61 |
DisclosureSEC source: 0000310158-03-000149 · wys259.xml · nonDerivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,081 Read SEC document |
| December 01, 2003 Filed Dec 3, 2003 21:37 UTC | Merck & Co., Inc. SGP · Entity 2807 | Exercise / conversionCommon Shares | 27,122 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000310158-03-000149 · wys259.xml · nonDerivative · entry 1 WYSZOMIERSKI JACK L · CIK 0001023225 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.